Does lateral lymph node dissection for low rectal cancer improve overall survival? Protocol for a systematic review and meta-analysis

IF 1.1 Q3 SURGERY

International Journal of Surgery Protocols Pub Date : 2019-01-01 DOI:10.1016/j.isjp.2019.09.001

Jeremy Meyer , Niki Christou , Christophe Combescure , Nicolas Buchs , Frédéric Ris

{"title":"Does lateral lymph node dissection for low rectal cancer improve overall survival? Protocol for a systematic review and meta-analysis","authors":"Jeremy Meyer , Niki Christou , Christophe Combescure , Nicolas Buchs , Frédéric Ris","doi":"10.1016/j.isjp.2019.09.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The best therapeutic strategy for treating lateral lymph nodes in patients with advanced mid to low rectal cancer remains unknown. Our objective is to determine which therapeutic strategy – lateral lymph node dissection <em>versus</em> radiochemotherapy – offers the best overall and recurrence-free survivals for these patients.</p></div><div><h3>Methods and analysis</h3><p>We will perform a systematic review and meta-analysis aiming at determining the overall and recurrence-free survivals of patients with total mesorectum excision with and without lateral lymph node dissection, in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. MEDLINE, Embase, Cochrane and Web of Science will be searched from inception to the 16th of January 2019 for original studies written in English or in French including patients who benefited from lateral lymph node dissection for low rectal cancer and reporting overall survival for patients with and without lateral lymph node dissection. Hazard ratios of overall and recurrence-free survivals extracted from included studies will be combined and compared between patients with and without lateral lymph node dissection. Risk of bias will be assessed by using the Newcastle-Ottawa scale.</p><p>The systematic review and meta-analysis protocol is registered in the International Prospective Register of Ongoing Systematic Reviews (PROSPERO) with number CRD42019123181.</p></div><div><h3>Ethics and dissemination</h3><p>No ethical clearance is required for this study. This review will be published in a peer- reviewed journal and will be presented at various national and international conferences.</p></div>","PeriodicalId":42077,"journal":{"name":"International Journal of Surgery Protocols","volume":"17 ","pages":"Pages 1-2"},"PeriodicalIF":1.1000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.isjp.2019.09.001","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgery Protocols","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468357419300373","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction

The best therapeutic strategy for treating lateral lymph nodes in patients with advanced mid to low rectal cancer remains unknown. Our objective is to determine which therapeutic strategy – lateral lymph node dissection versus radiochemotherapy – offers the best overall and recurrence-free survivals for these patients.

Methods and analysis

We will perform a systematic review and meta-analysis aiming at determining the overall and recurrence-free survivals of patients with total mesorectum excision with and without lateral lymph node dissection, in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. MEDLINE, Embase, Cochrane and Web of Science will be searched from inception to the 16th of January 2019 for original studies written in English or in French including patients who benefited from lateral lymph node dissection for low rectal cancer and reporting overall survival for patients with and without lateral lymph node dissection. Hazard ratios of overall and recurrence-free survivals extracted from included studies will be combined and compared between patients with and without lateral lymph node dissection. Risk of bias will be assessed by using the Newcastle-Ottawa scale.

The systematic review and meta-analysis protocol is registered in the International Prospective Register of Ongoing Systematic Reviews (PROSPERO) with number CRD42019123181.

Ethics and dissemination

No ethical clearance is required for this study. This review will be published in a peer- reviewed journal and will be presented at various national and international conferences.

查看原文本刊更多论文

低位直肠癌的侧淋巴结清扫能提高总生存率吗?系统评价和荟萃分析方案

晚期中低位直肠癌患者外侧淋巴结的最佳治疗策略尚不清楚。我们的目的是确定哪种治疗策略-侧淋巴结清扫与放化疗-为这些患者提供最佳的总体生存率和无复发生存率。方法和分析我们将根据系统评价和荟萃分析(PRISMA)声明的首选报告项目，进行系统评价和荟萃分析，旨在确定伴有或不伴有侧淋巴结清扫的全直肠系膜切除术患者的总体生存率和无复发生存率。MEDLINE、Embase、Cochrane和Web of Science将检索从开始到2019年1月16日用英语或法语撰写的原始研究，包括受益于低位直肠癌侧淋巴结清扫的患者，以及报告有无侧淋巴结清扫患者的总生存期。从纳入的研究中提取的总生存率和无复发生存率的风险比将被合并，并在有无侧淋巴结清扫的患者之间进行比较。偏倚风险将通过纽卡斯尔-渥太华量表进行评估。该系统评价和荟萃分析方案已在国际前瞻性正在进行的系统评价登记册(PROSPERO)注册，编号为CRD42019123181。伦理与传播本研究不需要伦理许可。这篇综述将发表在同行评议的期刊上，并将在各种国内和国际会议上发表。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Surgery Protocols SURGERY-

自引率

0.00%

发文量

期刊介绍： IJS Protocols is the first peer-reviewed, international, open access journal seeking to publish research protocols across across the full breadth of the surgical field. We are aim to provide rapid submission to decision times whilst maintaining a high quality peer-review process.